NPPB and hydrops fetalis: Finally, the reported NT-proBNP rise after 48 weeks of sacubitril/valsartan therapy (e.g., PROVE-HF and PARAGON-HF) was generally modest, clinically non-significant, and potentially related to assay variability or physiological adaptation, rather than indicative of worsening HF.